17 patents currently held
15 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jul 2034. from the record
Of the 15 now held by other companies, 7 name Jiangsu Aosaikang Pharmaceutical Co. Ltd. as their current owner, and 8 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jul 2034
Next term end
12
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Nov 2038 · High confidence
Also notable
Ends Mar 2040 · High confidence
Also notable
Ends Jul 2034 · High confidence
A Method for Treating or Preventing Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)
US 11,596,667
Cited by 4 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2038.
Abiraterone Prodrugs
US 10,792,292
A family of 13 related applications built on the 2020 grant. Protection runs to 2040.
Methods for Treating or Preventing Ophthalmological Conditions
US 11,273,171
A family of 8 related applications built on the 2022 grant. Protection runs to 2034.
Formerly held, still cited
Notable
Ends Jan 2036 · High confidence
The most cited patent in this portfolio, cited by 17 later US patents, top 25% of utility patents granted in 2018 in our data. Protection runs to 2036.
now held by Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Also notable
Ends Oct 2036 · Low confidence
Cited by 3 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2036. A terminal disclaimer caps this term to an earlier patent's.
now held by The Salk Institute for Biological Studies
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Aug 27, 2027The maintenance fee for Aryl Alkynamide Derivatives (US 11,912,679) comes due Aug 27, 2027. Unpaid by Feb 28, 2028, it lapses early.
- 1 fee due Oct 16, 2027The maintenance fee for Abiraterone Prodrugs (US 11,957,696) comes due Oct 16, 2027. Unpaid by Apr 17, 2028, it lapses early.
Recent changes
- 1 term has ended since Aug 17, 2026
What they patent
The 5 largest of its 12 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Abiraterone Prodrugs | 3 in force | to Jun 2040 |
| Methods for Treating or Preventing Ophthalmological Conditions | 3 in force | to Jul 2034 |
| Poly-Adp Ribose Polymerase (PARP) Inhibitors | 2 in force | to Jun 2038 |
| Aryl Alkynamide Derivatives | 1 in force | to Feb 2043 |
| CD38 Inhibitors | 1 in force | to Sep 2042 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,273,171 | Methods for Treating or Preventing Ophthalmological Conditions In force · High confidence | In force | High confidence | |
| US 11,491,176 | Methods for Treating or Preventing Ophthalmological Conditions In force · High confidence | In force | High confidence | |
| US 12,016,875 | Methods for Treating or Preventing Ophthalmological Conditions In force · High confidence | In force | High confidence | |
| US 10,874,641 | Methods of Treating Acute Kidney Injury In force · High confidence | In force | High confidence | |
| US 11,034,670 | Poly-Adp Ribose Polymerase (PARP) Inhibitors In force · High confidence | In force | High confidence | |
| US 11,993,585 | Poly-Adp Ribose Polymerase (PARP) Inhibitors In force · Medium confidence | In force | Medium confidence | |
| US 11,596,667 | A Method for Treating or Preventing Idiopathic Polypoidal Choroidal Vasculopathy (IPCV) In force · High confidence | In force | High confidence | |
| US 12,600,986 | Nucleic Acid Molecules Containing Spacers and Methods of Use Thereof held by Astellas Gene Therapies, Inc. In force · Low confidence | In force | Low confidence | |
| US 10,792,292 | Abiraterone Prodrugs In force · High confidence | In force | High confidence | |
| US 11,559,534 | Abiraterone Prodrugs In force · High confidence | In force | High confidence |
Also on record, not counted in the 17: 15 patents in force now held by others · 14 patents ended · 25 applications pending · 17 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.